adenoviral vectors have shown great promise as vaccine carriers and in gene transfer to correct underlying genetic diseases. traditionally, construction of adenoviral vectors is complex and time consuming. In this paper, we provide an improved method for efficient generation of novel adenoviral vectors by using direct cloning. We introduce a feasible and detailed protocol for the development of chimpanzee adenoviruses (ads) as molecular clones, as well as for the generation of recombinant virus from the molecular clones. recombinant viruses are genetically stable and induce potent immune responses in animals. Generation of new ad molecular clones or new recombinant ad can be achieved in 2 months or 2 weeks, respectively.
IntroDuctIon
Vectors based on Ads are commonly used for gene transfer because of their broad tropism, high transduction efficiency and relatively low risk in safety. Until now, most vectors are based on human serotype 5 (AdHu5). This virus is endemic in most human populations, and neutralizing antibodies specific to AdHu5 can be detected in up to 40-60% of humans 1 . Pre-existing neutralizing antibodies dampen gene transfer efficacy and increase vector-mediated toxicity 2 . Vectors based on rare human Ad serotypes and Ad from other species are being explored to overcome the impact of pre-existing immunity [1] [2] [3] [4] [5] [6] . Three major methods have traditionally been used to generate recombinant Ad vectors. The most commonly used method is based on homologous recombination in a packaging cell line. In this method, the gene of interest is cloned into a shuttle vector and concomitantly transfected with the Ad genome into HEK 293 cells or other cells that provide E1 in trans. Recombination between the shuttle vector and the Ad genome replaces the E1 domain with the gene of interest. However, recombination is relatively rare and the isolation of recombinant Ad vector using this method is laborious, time consuming and requires multiple rounds of plaque purification 7 . The second method is based on homologous recombination in Escherichia coli. The commercially available pAdEasy system is based on this method. It is efficient but more complex and requires a three-step transformation, including the use of two different E. coli strains 8, 9 . The third method is based on direct cloning of the Ad genome into a plasmid vector. The genome can then be manipulated in vitro and, following transfection into a packaging cell line, the virus can be rescued. This method is technically challenging because the Ad genome is large (around 36 kb) and contains few useful restriction sites that allow its assembly into a full-length molecular clone 8 . However, this method is highly desirable, because it is straightforward and it completely eliminates potentially contaminating infectious material from the original Ad genome 10 that would not be eliminated by homologous recombination and thus affect the usefulness of Ad vectors for clinical development.
In this paper, we describe a simple strategy that allows the efficient development of Ad molecular clones by direct cloning. Briefly, we took advantage of suitable unique restriction sites within a portion of the genome rather than within the whole genome. Such sites are present in all Ad genomes that we have vectored thus far. Thereafter, we assembled the genome part by part into one plasmid. To clone the foreign gene of interest into the Ad molecular clone, a shuttle vector was used containing two very rare restriction sites, I-CeuI and PI-SceI. The same sites were placed into the molecular clone to allow the insertion of the transgene's expression cassette into the deleted E1 domain. Virus can be rescued by transfection of packaging cell lines with the linearized recombinant molecular clone.
Overview of the protocol
This protocol describes the development of an E1-or E1/E3-deleted Ad molecular clone and the cloning of the gene of interest into the E1/E3-deleted Ad genome, using chimpanzee-derived Ad serotype 6 (AdC6) as an example. The Ad genome contains four segments that encode early gene products (E1-E4), and five segments that encode five late gene products (L1-L5). The E1, E2 and E4 gene products regulate transcription and translation of late genes and are necessary for viral replication. E3 gene products subvert immune responses by altering antigen presentation and cytokine and apoptosis pathways, but are unnecessary for viral replication 11 . Deletion of the E3 in addition to the E1 domain increases the permitted size of the inserted expression cassette to ~7.5 kb.
To generate the E1-deleted AdC6 molecular clone, the 5′ rightinverted terminal repeat (ITR) was amplified by PCR and cloned into the pNEB193 vector. Using restriction enzyme sites that are unique in assembly but not necessarily unique to the full AdC6 genome, the right half of the AdC6 genome was then cloned piecemeal into the pNEB193 vector. The left ITR was amplified by PCR and cloned into a different pNEB193 vector. Using the same strategy as above, the remainder of the left fragment of the AdC6 genome was assembled into the pNEB193 vector. Approximately 2.6 kb of the E1 region between SnaBI and NdeI sites was omitted and replaced with a linker that contains the rare enzyme sites of ICeuI and PI-SceI. This step removes the entire E1a and E1b 19-kDa homolog-coding regions and 74% of the E1b 55-kDa homologcoding region. Finally, using two suitable enzymes, the E1-deleted left fragment of the Ad genome was released from the pNEB193 vector and inserted into the vector containing the right fragment of the genome, effectively generating the E1-deleted infectious molecular clone of AdC6.
To delete the E3 domain, a fragment including this domain was cut from the E1-deleted molecular clone. The ends of the molecular clone were recombined by ligation. The ~4 kb E3 region was removed from the fragment using suitable restriction enzymes, i.e., Eco47III and SwaI. The resulting fragment was then cloned back into the E1-deleted molecular clone to generate the E1/E3-deleted Ad molecular clone.
To generate a recombinant molecular clone, first, the gene of interest was cloned into the commercially available pShuttle vector under the control of CMV promoter; other promoters can also be used (see Box 1). The expression cassette was released by digestion with I-CeuI and PI-SceI, and then cloned into the Ad molecular clone that had been cut with the same enzymes. Recombinant Ad vector was generated by rescue in packaging cells such as HEK 293 cells (see Box 2).
This protocol is direct, efficient and reproducible. Provided the sequence of the Ad genome is known, molecular clone generation from a purified Ad averages 2 months and a recombinant Ad vector can be efficiently generated and purified to high titers within an additional 2 weeks. Ads can be cloned as vectors for vaccine development or gene transfer with the use of this protocol. Data obtained from a molecular clone of chimpanzee-derived Ad serotype 7 (AdC7) are also shown. 
Results obtained previously using this protocol
• • • • • • • • • • • • • • • •
Box 2 | PACKAGING CELL LINES
Chimpanzee-origin adenovirus (Ad) vectors can readily be grown in packaging cell lines that provide E1 of AdHu5 in trans. HEK 293 cells are freely available to academic investigators. Some of the E1-deleted AdHu5 genomes may recombine with the E1 gene of the packaging cell line, resulting in a replication-competent Ad virus. The E1 flanking regions of chimpanzee-origin Ad viruses show limited homology with those of AdHu5, making recombination in HEK 293 cells highly unlikely. Other E1 transcomplementing packaging cell lines have been described such as PERC6 cells 38 , which are not readily available to academia. Some E1-deleted Ad serotypes cannot be rescued on cell lines that provide E1 of AdHu5 virus in trans. Examples are the chimpanzee-origin AdC1 vector or human serotypes AdHu26 or AdHu35 (refs. 25, 39) . For such vectors, the open reading frame 6 of E4 has to be replaced with that of AdHu5 virus. Again, such replacement can be made in the viral molecular clone using cloning techniques similar to those described above. 29 . The number of virus particles (vp) per milliliter was determined by measuring UV absorbance at 260 nm (A 260 ) using a spectrophotometer and was calculated using the following equation 30 • Mix the reaction by vortexing and spin down. Run the PCR for 32 cycles at 94 °C for 1 min, 58 °C for 1 min and at 72 °C for 2.5 min.
6| Digest 12 µl of the PCR amplicon with KpnI and EcoRI for 2 h at 37 °C. Conduct digestion in a total volume of 20 µl.
7|
Run the digestion products on 1% (wt/vol) low-melting agarose gel in TAE buffer. Cut out the bands and place gel slices into Eppendorf tubes. Incubate for 5 min at 68 °C. Cool for 1 min at 37 °C. Set up an in-gel ligation reaction in a total volume of 20 µl, i.e., use 4 µl of vector in liquefied gel, 12 µl of insert in liquefied gel and mix both with 1 µl of 5 U of T4 DNA ligase. Ligate at 16 °C overnight.  crItIcal step Heating the gel slices containing DNA for 5 min at 68 °C is enough to melt the agarose. Try not to exceed 70 °C to avoid denaturing the DNA. For this and all subsequent cloning steps, confirmation that the desired clone was obtained is made by restriction enzyme digestion, and a fragment of DNA is sequenced to ensure correct ligation. In our example, the new construct was termed PNEB193 + EK (Fig. 1) NdeI (2738) MluI (2885) MluI (2746) PmeI (2257) PmeI (2257) PI-Scel (2806) I-Ceul (2780) PmeI (2257) MluI (14966) NdeI ( In brief, one fragment including E3 domain was cut from E1-deleted molecular clone, E3 region was then removed from the fragment by digestion of Eco47III and SwaI. Finally, the resulting fragment was cloned back into E1-deleted molecular clone.
21| Digest 12 µl of PCR amplicon with PmeI for 3 h at 37 °C; thereafter, add 1.5 µl of BstAPI and incubate for 3 h at 60 °C. Conduct digestion in a total volume of 30 µl.
22|
Repeat Steps 7-9. Both PmeI and BstAPI sites are unique in this part of the genome. The new construct was termed PNEB193 + PB. 
23|

36|
Run the digest on 1% (wt/vol) low-melting agarose gel in TAE buffer; cut out a band containing a fragment of ~19 kb and place it into an Eppendorf tube. Incubate for 5 min at 68 °C. Cool for 1 min at 37 °C. Assemble an in-gel ligation reaction as described in Step 7.
37|
Repeat Steps 8 and 9. The ligation results in the new construct AdC6-Sbf1. 38| Digest 0.5 µg of AdC6-Sbf I plasmid DNA with Eco47III and SwaI. Both of these enzyme sites are unique in this plasmid and both enzymes produce blunt ends. Conduct the reaction in a total volume of 20 µl and incubate for 3 h at 37 °C.
39|
Run all digests on 1% (wt/vol) low-melting agarose gels in TAE buffer; cut out a band containing a fragment of ~15 kb and place it into an Eppendorf tube. Heat for 5 min at 68 °C. Cool down for 1 min at 37 °C. Conduct an in-gel ligation as described in Step 7. 64| Run all digests in 1% (wt/vol) agarose gel to determine whether they have the correct fragments (shown in Fig. 3a) . 67| After 24 h, harvest cells and resuspend in 100 µl of RIPA buffer with protease inhibitors.
40|
68|
Run the western blot to detect the expression of HIV gag by blotting with an anti-HIV Gag antibody. β-Actin is included as a loading control (Fig. 3b) . ? trouBlesHootInG Troubleshooting advice can be found in table 1.
• Determine quality of plasmid DNA and optimal ratio of DNA in transfection mix; sequence key regions of the molecular clone based on amplification of Ad vectors in suspension cultures have been described previously 33 . Viruses should remain stable on serial passages. After immunization, vectors should elicit readily detectable transgene product-specific CD8 + T-cell responses (Fig. 4) .
Depending on the transgene product, other methods may have to be used to test for immune responses. Transgene products designed to induce B-cell responses should be tested for induction of antibodies from serum or plasma by suitable assays such as neutralization assays for viral glycoproteins or enzyme-linked immunosorbent assays for antigens that fail to elicit neutralizing antibodies. B-cell responses can be enumerated by ELISpot assays for antibody-secreting cells or memory B cells 34 . Induction of antibody responses can be assessed in inbred or outbred strains of mice. Induction of T cells can be tested for by a variety of assays if T-cell epitopes or their restricting elements are not defined; the definition of both is a prerequisite for the development of tetramers. Alternative T cell assays include intracellular cytokine staining upon a short in vitro stimulation of lymphocytes with their cognate antigen; ELISpot assays, which do not distinguish between CD8 + and CD4 + T-cell subsets, unless one of these subsets is depleted from the lymphocyte preparation before analyses; and others such as 51 Cr-release or cytokine-release assays, which assess function rather than magnitude of a T-cell response. It should be noted that Ad vectors induce preferentially potent CD8 + T-cell responses, whereas induction of CD4 + T-cell responses is less prominent. Attention should be paid to the presence of a suitable T-cell epitope within the transgene product when selecting a mouse strain for immunogenicity testing of Ad vectors. In cases in which the transgene product lacks an epitope that can be recognized by T cells of any of the available inbred mouse strains, testing may have to be conducted in another species or in HLA transgenic mice 35 . The timeline described above is based on our experience with AdC6. A number of problems can be encountered during the procedures, and this can significantly expand the time line. Problems we have encountered in the past included contamination of wild-type Ad virus with variants, which required repeated cloning of the virus by plaque purification (add ~4 weeks); inaccurate sequence information, which did not identify all of the sites for restriction enzymes we had planned to use (add anywhere from 1 to 8 weeks if the viral genome has to be resequenced or if a new cloning strategy has to be developed and implemented); problems with ligations (add ~3-6 d); and, most worrisome, problems with viral rescue. We typically try at first to rescue a molecular clone that does not carry a transgene. If virus cannot be rescued, it commonly means that the molecular clone is flawed, which can best be detected by sequencing of key regions (ITRs and regions that could have been modified during cloning). 
